Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(13 sites)
United States
UCLA Hematology/Oncology, Santa Monica, California SCRI at HealthOne, Denver, Colorado Florida Cancer Specialists, Sarasota, Florida Dana Farber Cancer Institute, Boston, Massachusetts Henry Ford Health System, Detroit, Michigan START MidWest, Grand Rapids, Michigan NYU Langone Hematology Oncology Associates-Mineola, Mineola, New York New York University Langone Health, New York, New York Sarah Cannon Tennessee Oncology, Nashville, Tennessee US Oncology Investigational Products Center, Dallas, Texas The University of Texas MD Anderson Cancer Center, Houston, Texas NEXT Oncology Virginia, Fairfax, Virginia US Oncology Investigational Products Center, Norfolk, Virginia Last updated November 2025